These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 7792038)

  • 1. Changes in bone mineral content during long-term CAPD. Indication of a sex-dependent bone mineral loss.
    Lyhne N; Pedersen FB
    Nephrol Dial Transplant; 1995; 10(3):395-8. PubMed ID: 7792038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of ionized calcium and 1,25-dihydroxycholecalciferol loss from peritoneal fluid during peritonitis in patients treated with continuous ambulatory peritoneal dialysis.
    Lin CY; Huang TP
    Nephron; 1991; 59(1):90-5. PubMed ID: 1944754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of bone mineral density in CAPD patients with dual energy X-ray absorptiometry.
    Pasadakis P; Thodis E; Mourvati E; Euthimiadou A; Margaritis D; Manavis J; Vargemezis V
    Adv Perit Dial; 1996; 12():245-9. PubMed ID: 8865913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cessation of bone loss in chronic renal failure by 1-alpha-hydroxyvitamin D3: a controlled trial.
    Madsen S; Olgaard K; Ladefoged J
    Proc Eur Dial Transplant Assoc; 1978; 15():517-23. PubMed ID: 311003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress of renal osteodystrophy during continuous ambulatory peritoneal dialysis.
    Buccianti G; Bianchi ML; Valenti G
    Clin Nephrol; 1984 Dec; 22(6):279-83. PubMed ID: 6525771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1 alpha-hydroxy vitamin D3 treatment of non-dialyzed patients with chronic renal failure. Effects on bone, mineral metabolism and kidney function.
    Nielsen HE; Rømer FK; Melsen F; Christensen MS; Hansen HE
    Clin Nephrol; 1980 Mar; 13(3):103-8. PubMed ID: 7379358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of calcifediol treatment on the progression of renal osteodystrophy during continuous ambulatory peritoneal dialysis.
    Buccianti G; Bianchi ML; Valenti G; Lorenz M; Cresseri D
    Nephron; 1990; 56(4):353-6. PubMed ID: 2079992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of combined 24,25(OH)2D3 and 1 alpha (OH)D3 therapy for bone disease in dialysis patients.
    Popovtzer MM; Levi J; Bar-Khayim Y; Shasha SM; Boner G; Bernheim J; Chaimovitz C; Rubinger D; Gafter U; Gazit D
    Bone; 1992; 13(5):369-77. PubMed ID: 1419378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal osteodystrophy in children undergoing continuous ambulatory peritoneal dialysis.
    Hewitt IK; Stefanidis C; Reilly BJ; Kooh SW; Balfe JW
    J Pediatr; 1983 Nov; 103(5):729-34. PubMed ID: 6631599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics of menatetrenone and effects on bone metabolism in continuous ambulatory peritoneal dialysis patients.
    Sugimoto T; Yamakado M; Matsushita K; Iwamoto T; Tagawa H
    J Int Med Res; 2002; 30(6):566-75. PubMed ID: 12526283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of 1 alpha-OH-D3 on bone mineral content in the forearm of chronic hemodialyzed patients.
    Manji T; Kobayashi K
    Contrib Nephrol; 1980; 22():39-50. PubMed ID: 7398338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1,25-dihydroxycholecalciferol in patients with chronic renal failure.
    Henderson RG; Ledingham JG; Norman AW; Oliver DO; Preston C; Russell RG; Small DG; Smith R; Warner GT; Woods CG
    Proc Eur Dial Transplant Assoc; 1973; 10(0):202-9. PubMed ID: 4802654
    [No Abstract]   [Full Text] [Related]  

  • 15. Losses of 25-hydroxyvitamin D in peritoneal fluid: possible mechanism for bone disease in uremic patients treated with chronic ambulatory peritoneal dialysis.
    Aloni Y; Shany S; Chaimovitz C
    Miner Electrolyte Metab; 1983; 9(2):82-6. PubMed ID: 6601753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal osteodystrophy in CAPD patients.
    Zucchelli P; Catizone L; Casanova S; Fusaroli M; Fabbri L; Ferrari G
    Miner Electrolyte Metab; 1984; 10(5):326-32. PubMed ID: 6493161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1 alpha hydroxycholecalciferol and 25 hydroxycholecalciferol in renal bone disease.
    Fournier AE; Bordier PJ; Gueris J; Chanard J; Marie P; Ferriere C; Osario M; Bedrossian J; de Luca HF
    Proc Eur Dial Transplant Assoc; 1976; 12():227-36. PubMed ID: 935115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal osteodystrophy and metastatic calcification in long-term continuous ambulatory peritoneal dialysis.
    Cassidy MJ; Owen JP; Ellis HA; Dewar J; Robinson CJ; Wilkinson R; Ward MK; Kerr DN
    Q J Med; 1985 Jan; 54(213):29-48. PubMed ID: 3975345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bone and joint complications in patients treated with continuous ambulatory peritoneal dialysis (CAPD) for more than 3 years].
    Dratwa M; Wens R; Collart F; Tielemans C
    Nephrologie; 1989; 10 Suppl():56-61. PubMed ID: 2812191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone mineral content in patients on prolonged maintenance hemodialysis: a three year follow-up study.
    Rickers H; Christensen M; Rødbro P
    Clin Nephrol; 1983 Dec; 20(6):302-7. PubMed ID: 6641032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.